Newsroom

latest news from ose
and across our portfolio

Featured News

Oxford Spinout Oxford Semantic Technologies acquired by Samsung Electronics
Oxford Spinout Oxford Semantic Technologies acquired by Samsung ElectronicsArticle links to www.oxionics.com
Oxford Ionics breaks global quantum performance records
Oxford Ionics breaks global quantum performance records
Times Commentary: Science innovation must be at the heart of government action
Times Commentary: Science innovation must be at the heart of government actionArticle links to www.beacontx.com
Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies
Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene TherapiesArticle links to www.prnewswire.com
PQShield raises $37m in Series B funding to deliver the widespread commercial adoption of quantum resistant cryptography
PQShield raises $37m in Series B funding to deliver the widespread commercial adoption of quantum resistant cryptographyArticle links to www.globenewswire.com
Amber Therapeutics Closes $100 Million Series A - one of the largest European MedTech raises
Amber Therapeutics Closes $100 Million Series A - one of the largest European MedTech raisesArticle links to www.businesswire.com
SpyBiotech Adds Epstein-Barr Virus Research and Development Collaboration with The University of Oxford
SpyBiotech Adds Epstein-Barr Virus Research and Development Collaboration with The University of Oxford
OSE announces groundbreaking new partnership with The Crown Estate and Pioneer Group
OSE announces groundbreaking new partnership with The Crown Estate and Pioneer Group

All News

Portfolio NewsOMass TherapeuticsOMass Therapeutics Strengthens its Leadership Team with the Promotions of Hsin Loke to Chief Operating officer and Jon Roffey to Senior Vice President, Discovery and Non-ClinicalPortfolio NewsOMass TherapeuticsOMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah TeichmannPortfolio NewsOMass TherapeuticsCEO Ros Deegan appointed to UK Prime Minister's Business CouncilPortfolio NewsOMass TherapeuticsOMass Therapeutics expands leadership team with the appointment of Melissa Faris as Chief Business OfficerPortfolio NewsOMass TherapeuticsOMass Therapeutics Adds Mark Namchuk, PhD to Scientific Advisory BoardPortfolio NewsOMass TherapeuticsOMass Therapeutics Announces Appointment of New Board Chair and Series B ExtensionPortfolio NewsOMass TherapeuticsOMass Therapeutics Announces New Phase of Growth with Move to New Facilities and Team Expansion to Support Portfolio ProgressPortfolio NewsOMass TherapeuticsPublication in Nature Chemistry between Omass Therapeutics and co-founder Dame Carol Robinson demonstrates the benefits of native mass spectrometry in the interrogation of target ecosystems and drug discoveryPortfolio NewsOMass TherapeuticsOMass Therapeutics appoints Dr Jon Roffey as Vice President, Head of Medicinal ChemistryPortfolio NewsOMass TherapeuticsOMass Therapeutics raises $100 million in Series B financing to progress drug pipeline in immunology and rare diseasesPortfolio NewsOMass TherapeuticsPublication in Nature by OMass Founder, Professor Dame Carol Robinson, shows power of native mass spectrometry in drug discoveryPortfolio NewsOMass TherapeuticsOMass Therapeutics establishes scientific advisory board of leading expertsPortfolio NewsOMass TherapeuticsOmass Therapeutics OdyssION™ drug discovery platform makes progress in drugging the undruggablePortfolio NewsOMass TherapeuticsOMass Therapeutics unveils rich drug discovery pipeline targeting intractable or inadequately drugged membrane and complex-bound proteins